Tesaro - Moonstone for Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

What is the Purpose of this Study?

We are doing this study to learn how safe and effective the study drugs (Niraparib and TSR-042) are to treat platinum-resistant ovarian cancer.
What is the Condition Being Studied?
Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who Can Participate in this Study?

Adults who:

- Have relapsed ovarian, Fallopian tube, or primary peritoneal cancer

- Have had no more than 3 prior treatments for your cancer

Age Group
Adults
Participating Institutions

What is Involved?

If you choose to join this study you will:

- Take the study drug (Niraparib) for 3 weeks

- Get an infusion (into your vein) of the study drug (TSR-042) once a week for 3 months

- Get a physical every 3 weeks

Study Details

Full Title
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (Moonstone)
Principal Investigator

Protocol Number
IRB:
PRO00102918

NCT:
NCT03955471
ClinicalTrials.gov
View on ClinicalTrials.gov